Pharma & Healthcare: Export growth accelerates; USFDA compliance costs moderate — PreRatings
Infrastructure Developer — Long Term AA−
Pharma Manufacturer — Long Term AA+
Regional NBFC — NCD Rating BBB+
Steel Producer — Bank Loan A
Textile Exporter — Long Term BB+
Auto Component Mfr — Short Term A1+
Cement Producer — Long Term AA
Chemical Exporter — IPO Grading A−
Infrastructure Developer — Long Term AA−
Pharma Manufacturer — Long Term AA+
Regional NBFC — NCD Rating BBB+
Steel Producer — Bank Loan A
Textile Exporter — Long Term BB+
Auto Component Mfr — Short Term A1+
Cement Producer — Long Term AA
Chemical Exporter — IPO Grading A−
← Back to PreRatings
Insight · Sector

Pharma & Healthcare: Export growth accelerates; USFDA compliance costs moderate

28 Jul 2026 Insight PreRatings Research
Generic drug exports grew 14% YoY. ANDA approval velocity at USFDA has improved, reducing regulatory overhang for mid-cap pharma companies. 7 of 10 rated companies show stable or positive outlook.
Healthcare & Pharma Export